SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Biogen
An SI Board Since August 1996
Posts SubjectMarks Bans Symbol
1686 75 0 BIIB
Emcee:  Harold Engstrom Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
1611wsj: Biogen Considers a Sale; Pressure Comes From Icahn By KEITH J. WINSTEIN Octmopgcw-10/13/2007
1610Preclinical Study Published in Nature Medicine Shows Anti-LINGO-1 Antibody Promokeokalani'nui-9/30/2007
1609Bursting Biogen Idec's Bubble Biogen Idec (BIIB: Nasdaq) By UBS Investment Rmopgcw-9/17/2007
1608Biogen Idec Initiates Phase III Trial of Galiximab for Follicular Non-Hodgkinnigel bates-1/25/2007
1607Phase I/II Data Support Continued Development of Biogen Idec's Novel Anti-CDnigel bates-12/11/2006
1606gs: During our conference call on September 13, 2006, Biogen Idec management focmopgcw-9/14/2006
1605Rituxan Is Promising in MS Trial By a WALL STREET JOURNAL Staff Reporter AugustDoc Bones-8/29/2006
1604wsj:Elan Looks to Relaunch Tysabri By QUENTIN FOTTRELL May 4, 2006 10:51 a.m. mopgcw-5/5/2006
1603UPDATE 1-Elan, Biogen eye Tysabri launch this summer in EU Fri Apr 28, 2006 8:27mopgcw-4/30/2006
1602Biogen: Avonex Delays MS Risk Monday April 3, 4:30 pm ET Biogen Idec Study SDoc Bones-4/4/2006
1601mstar: We are holding our opinions of Biogen Idec BIIB and Elan ELN steady aftmopgcw-3/22/2006
1600Biogen Idec - BIIB-NNM Sell/Sell Short - Price 45.51 on March 7 by Variant Reseamopgcw-3/12/2006
1599That's about 25c p/s in 2008. I suppose much of that is already built in, butom pope-3/7/2006
1598gs: BIIB(IL/N): Publication on Tysabri highlights potential discussions at FDA rmopgcw-3/6/2006
1597marketwatch.com BIIB and DNA said the Food and Drug Administration has approvedBiotech Jim-2/12/2006
1596Thanks George. eomfred hayes-1/30/2006
1595gs; BIIB (IL/N): FDA review of Tysabri set for 3/7/06, in line. Continue to expemopgcw-1/30/2006
1594Biogen Idec, Elan: FDA Committee To Review TYSABRI March 7 DOW JONES NEWSWIRES mopgcw-1/23/2006
1593Teva's Suesskind: Tysabri may come back, different and smaller {Hubris ?notmidastouch017-12/11/2005
1592citi/ssb q3 prev: Biogen Idec (BIIB, Hold, High Risk) Reporting date: Wednesdmopgcw-10/10/2005
1591Citigroup Investment Research BIIB: Restructuring Exps; Downgrading to Hold onmopgcw-9/12/2005
1590Heads roll at BIIB, Avonex remains the darling, Gilman gone biz.yahoo.comtom pope-9/8/2005
1589Avonex, Rituxan Power Biogen By Althea Chang TheStreet.com Staff Reporter 7/26Doc Bones-7/27/2005
1588Phase II Data Show Combination Biological Therapy with Galiximab and RITUXAN is mopgcw-6/15/2005
1587GS: BIIB (IL/N): Expect limited share impact from data on Tysabri and competitivmopgcw-6/15/2005
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News